AntiMyl Cancer Research Results

AntiMyl, Antiamyloidogenic: Click to Expand ⟱
Source:
Type:

Antiamyloidogenic Activity

Abbreviation: Antiamyloidogenic

Type: Therapeutic effect / functional outcome / protein-aggregation outcome

Function: Antiamyloidogenic activity describes the ability of a compound, treatment, or biological process to reduce amyloid formation, aggregation, accumulation, stability, or toxicity. In Alzheimer's disease research, this most commonly refers to inhibition of amyloid-β (Aβ) oligomerization, fibril formation, plaque accumulation, or promotion of amyloid clearance.

Alzheimer's Disease: ↑ Antiamyloidogenic activity is favorable because it reflects reduced formation or accumulation of toxic amyloid species and/or enhanced removal of existing amyloid aggregates.

Favorable Direction: ↑ Antiamyloidogenic activity.

Interpretation Note: Antiamyloidogenic activity is a broad functional outcome and should be distinguished from specific molecular effects such as Aβ42 ↓, BACE1 ↓, APP processing changes, fibril destabilization, or amyloid clearance ↑ when those endpoints are measured directly.



Scientific Papers found: Click to Expand⟱
8421- Lyco,    Lycopene: Sojourn from kitchen to an effective therapy in Alzheimer's disease
- Review, AD, NA
*neuroP↑, *antiOx↑, *Inflam↓, *AntiMyl↑, *ROS↓, *MMP↑, *NGF↑, *BDNF↑, *VEGF↑, *Aβ42↓, *PI3K↑, *Akt↑, *NRF2↑, *lipid-P↓, *GSH↑, *Catalase↑, *SOD↑, *cognitive↑, *Learn↑, *memory↑, *APP↓, *BACE/β-secretase↓, *ADAM10↑, *NF-kB↓, *AChE↓, *MAOA↓, *BioAv↝,
8657- MLT,    Melatonin in Alzheimer's Disease: Literature Review and Therapeutic Trials
- Review, AD, NA
*toxicity↓, *Sleep↑, *antiOx↑, *AntiMyl↑, *p‑tau↓, *Aβ↓, *TC↓, *neuroP↑, *ROS↓, *BBB↑, *Learn↑, *memory↑, *Synergy↑, *Dose↝,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   Catalase↑, 1,   GSH↑, 1,   lipid-P↓, 1,   NRF2↑, 1,   ROS↓, 2,   SOD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↑, 1,   PI3K↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

VEGF↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   MMP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,   NF-kB↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   ADAM10↑, 1,   BDNF↑, 1,   MAOA↓, 1,   NGF↑, 1,  

Protein Aggregation(tgid=19) ⓘ

APP↓, 1,   Aβ↓, 1,   Aβ42↓, 1,   BACE/β-secretase↓, 1,   p‑tau↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   Dose↝, 1,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

TC↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiMyl↑, 2,   cognitive↑, 1,   Learn↑, 2,   memory↑, 2,   neuroP↑, 2,   Sleep↑, 1,   toxicity↓, 1,  
Total Targets: 35

Scientific Paper Hit Count for: AntiMyl, Antiamyloidogenic
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:1  prod#:%  Target#:1831  State#:%  Dir#:2
wNotes=0 sortOrder:rid,rpid

 

Home Page